Why Are Iveric Bio Shares Surging In Premarket Friday?

Iveric Bio Inc ISEE stock is trading almost 50% higher as the investors are cheering Stifel's initiated coverage on Iveric Bio with a Buy rating and a price target of $22.00.
Analyst Annabel Samimy comments that, though the Company is not a first mover in the still untapped Geographic Atrophy (GA) market, Iveric could very well be the leading treatment for this indication.
Zimura has demonstrated high statistical significance in the pivotal study and can potentially emerge as the only treatment that could prevent vision loss and function.
Related Content: Iveric Bio Reveals Positive Post-Hoc Analyses Of Zimura In Dry Age-Related Macular Degeneration.
Also See: FDA On SPA Agreement For Zimura Study In Geographic Atrophy.
Together, we see ISEE as building a unique platform for untapped retinal diseases," mentions the analyst.
Read Next: Iveric Bio Raises $100M Via Equity To Fund Zimura Development In Geographic Atrophy.
Price Action: ISEE stock is up 50.20% at $13.05 during the premarket session on the last check Friday.